Detalles de la búsqueda
1.
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Blood Cells Mol Dis;
68: 153-159, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27839979
2.
Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
Blood Cells Mol Dis;
59: 37-43, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27282565
3.
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Am J Hematol;
90(7): 584-91, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25801797
4.
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Am J Hematol;
88(3): 166-71, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23386328
5.
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Am J Hematol;
88(3): 179-84, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23400823
6.
Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016.
Blood Cells Mol Dis;
65: 71-72, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28576608
7.
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Leuk Lymphoma;
60(14): 3375-3385, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31272251
Resultados
1 -
7
de 7
1
Próxima >
>>